Genetic Technologies Limited (ADR)  

(Public, NASDAQ:GENE)   Watch this stock  
Find more results for GENE
-0.012 (-1.51%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.79 - 0.83
52 week 0.75 - 2.89
Open 0.83
Vol / Avg. 23,393.00/55,653.00
Mkt cap 11.52M
P/E     -
Div/yield     -
EPS -0.55
Shares 2.44B
Beta 2.44
Inst. own 0%

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -1103.20% -1025.84%
Operating margin -1103.20% -1025.84%
EBITD margin - -984.03%
Return on average assets -54.58% -49.74%
Return on average equity -61.09% -54.85%
Employees 64 -
CDP Score - -


60-66 Hanover St
Fitzroy, VIC 3065
+61-3-94151135 (Phone)
+61-3-84127040 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

Officers and directors

Eutillio Buccilli Chief Executive Officer, Executive Director
Bio & Compensation  - Reuters
Kevin Fischer Chief Financial Officer, Company Secretary
Bio & Compensation  - Reuters
Mark Ostrowski President of Phenogen Sciences Inc
Age: 50
Bio & Compensation  - Reuters
Richard Allman Ph.D Scientific Director
Age: 53
Bio & Compensation  - Reuters
M. Luisa Ashdown Director of Global Licensing and Intellectual Property
Age: 57
Bio & Compensation  - Reuters
Susan J. Gross M.D. Senior Medical Director
Bio & Compensation  - Reuters
Diana Newport Quality and Business Operations Director
Age: 56
Bio & Compensation  - Reuters
Malcolm Roy Brandon Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Grahame James Leonard Director
Bio & Compensation  - Reuters
Paul Alexander Kasian Non-Executive Director
Bio & Compensation  - Reuters